Hepatocellular Carcinoma News and Research

RSS

Hepatocellular Carcinoma is a type of adenocarcinoma, the most common type of liver tumor.

Novel targets for treating sorafenib-resistant hepatocellular carcinoma found using CRISPR-Cas9 screening

This study is led by Xiujun Cai (Department of General Surgery, Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine). Professor Xiujun Cai's research team screened the whole genome of hepatocellular carcinoma cells (HepG2) through CRISPR / cas9 system under sorafenib treatment, and screened the dominant gene in sorafenib resistance.

20 Apr 2022

Research shows tsRNA as a promising biomarker for early diagnosis of hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is the most primary liver cancer. It is one of the most common and mortal cancer worldwide, especially in East Asia. Advanced HCC patients expect a significantly low 5-year survival rate as well as poor prognosis.

18 Apr 2022

UCL researchers boost the effectiveness of therapeutic vaccine for chronic HBV

Scientists at UCL have significantly boosted the effectiveness of a therapeutic vaccine designed to control chronic hepatitis B (HBV) infection, after uncovering and thwarting 'the enemy within'.

13 Apr 2022

New trial aims to test a non-invasive treatment for early-stage liver cancer

Researchers are set to trial a non-invasive treatment for inoperable early-stage liver cancer, thanks to an injection of over $2 million in federal government funding.

25 Feb 2022

International Aspirin Foundation publishes a report on the work of highly commended investigators

The International Aspirin Foundation has published a report of the Winner and Highly Commended awardees, present at the prestigious Emerging Aspirin Investigator Award Ceremony.

18 Feb 2022

Researchers generate stable cell lines capable of producing various hepatitis B virus genotypes

A new study created stable cell lines capable of producing different genotypes of the hepatitis B virus (HBV), advancing understanding of each type's distinct virological features, treatment responses, and infectivity that could lead to new therapies against a virus infecting humans as far back as 4,500 years ago.

15 Feb 2022

Researchers find a way to interfere with the energy pathway that promotes liver cancer spread

The World Health Organization projects that starting in 2030, over a million people will die each year from liver cancer.

4 Feb 2022

Researchers develop new tool to determine patients' liver cancer risk after hepatitis C

Hepatitis C can now be effectively treated, thanks to modern drugs. However, despite having been cured, some patients can go on to develop liver cancer. Currently, biannual ultrasound screening is done to monitor for incipient cancer.

28 Jan 2022

Scientific review highlights the impact of coffee on digestive organs

A new scientific review, published in Nutrients, highlights coffee's effects on digestion and the gut, and its impact on organs involved in digestion.

19 Jan 2022

New pathways responsible for hepatocellular carcinoma identified

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. It is one of leading causes of cancer-related deaths globally, with more than 700,000 new cases and 600,000 estimated HCC deaths each year.

18 Jan 2022

ASTRO provides new guidance on the use of external beam radiation therapy for primary liver cancers

A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides guidance on the use of radiation therapy to treat adult patients with primary liver cancers using external beam radiation therapy (EBRT).

12 Jan 2022

Scientists describe dynamic genomic landscape of tumor heterogeneity in hepatocellular carcinoma

Clinician scientists and scientists from the National Cancer Centre Singapore and A*STAR's Genome Institute of Singapore, in collaboration with Singapore General Hospital, the National University Health System, Duke-NUS Medical School, Nanyang Technological University, and collaborators from China, Malaysia, Thailand and the Philippines, have described a dynamic genomic landscape of tumour heterogeneity in hepatocellular carcinoma (HCC).

13 Dec 2021

CRISPR/Cas9 gene editing enables sonodynamic therapy to effectively shrink tumors

Sonodynamic therapy uses ultrasound in combination with drugs to release harmful reactive oxygen species (ROS) at the site of a tumor.

8 Dec 2021

Direct-acting antivirals for HCV-related hepatocellular carcinoma reduces the risk of tumor progression

In a new cohort study of patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC), a disease with a high recurrence rate, researchers at the Osaka City University Graduate School of Medicine reported that after receiving cancer treatment, the oral administration of direct-acting antivirals (DAA) reduces the risk of tumor progression following recurrence of the liver disease.

25 Nov 2021

New score developed to predict outcome in liver cancer patients receiving immunotherapy

There are still no established biomarkers to predict the success of immunotherapy in patients with liver cancer.

22 Nov 2021

Oncologists use immunotherapy at faster rates for trial-ineligible patients, study finds

Cancer patients who are ineligible for clinical trials receive immune checkpoint inhibitors (ICI) at greater rates than patients who are trial eligible despite no survival benefit, according to a new study by researchers at the Perelman School of Medicine at the University of Pennsylvania.

9 Nov 2021

Targeting Shp2 in oncological treatments appears to worsen the disease

In recent years, much scientific effort and funding has focused on developing drugs that target an enzyme with the unwieldy name of Src homology 2-containing protein tyrosine phosphatase 2 or more briefly, Shp2.

9 Nov 2021

Exosomal and non-exosomal miRNAs may serve as biomarkers for HCV-related cirrhosis, liver cancer

Oncotarget published "Exosomal and non-exosomal miRNA expression levels in patients with HCV-related cirrhosis and liver cancer" which reported that patients with HCV-related cirrhosis are at risk for liver cancer development.

11 Oct 2021

CXCR6/CXCL16 axis has significant role in the immuno-pathogenesis of severe COVID-19

In a study published on the preprint server medRxiv*, scientists studying the SARS-CoV-2 genome have identified a region linked with the disease severity.

16 Sep 2021

Prognostic impact of common type of liver cancer depends on tumor size, research reveals

Researchers at the Department of Hepato-Biliary-Pancreatic Surgery, Osaka City University Graduate School of Medicine have shown that the prognostic impact of hepatocellular carcinoma (HCC), the most common type of liver cancer, is dependent on tumor size.

6 Sep 2021